Amarin | AMRN - Equity Capital And Reserves


Amarin reported $459.28M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amarin USD 459.28M 387K Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
BioCryst Pharmaceuticals USD -119.15M 268.74M Dec/2025
DBV Technologies USD 52.85M 33.37M Sep/2025
Esperion Therapeutics USD -301.96M 149.4M Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Novartis USD 46.13B 1.38B Dec/2025